Title

A Study of Econazole Foam 1% in Athlete's Foot
A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Intervention/Treatment

    econazole ...
  • Study Participants

    135
This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam -- econazole nitrate 1% -- is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot. This study will help to understand if the foam works the same as the cream to treat athlete's foot.
Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear. A foam formulation that spreads easily and rubs-in easily that is as effective as the (reference) cream formulation in treating athlete's foot would be a benefit to the user. This study is designed to substantiate a clinical bridge between econazole nitrate foam 1% and econazole nitrate cream 1% based on clinical outcome, safety, and pharmacokinetic data. The study is (foam) vehicle-controlled and is randomized 1 to 1 to 1 (foam:cream:vehicle).
Study Started
Mar 31
2008
Primary Completion
Sep 30
2008
Study Completion
Oct 31
2008
Results Posted
Jan 09
2013
Estimate
Last Update
Jan 09
2013
Estimate

Drug Econazole Nitrate Cream 1%

Topical cream, applied once daily for 4 weeks.

  • Other names: Econazole Nitrate Cream 1%, Fougera - Altana Inc.

Drug Econazole Nitrate Foam 1%

Topical foam, applied once daily for 4 weeks.

  • Other names: Quinnova Econazole Nitrate Foam 1%

Drug Vehicle Foam

Topical foam, applied once daily for 4 weeks.

  • Other names: Quinnova Foam Vehicle

1 Active Comparator

Econazole Nitrate Cream 1%

2 Experimental

Econazole Nitrate Foam 1%

3 Placebo Comparator

Vehicle Foam

Criteria

Inclusion Criteria:

Be at least 18 years or age and of either sex.
Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only).
Be willing to give informed consent.
Be willing and able to give informed consent.
Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal).

Exclusion Criteria:

Is nursing or planning a pregnancy during the study.
Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study.
Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed.
Has any other skin disease which might interfere with the evaluation of tinea pedis.
Is currently enrolled in an investigational drug or device study.
Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study
Is unreliable, including subjects with a history of drug or alcohol abuse.
Has known hypersensitivity to any of the components of the study medications.

Summary

Reference Drug

Test Drug

Control

All Events

Event Type Organ System Event Term Reference Drug Test Drug Control

Complete Cure Rate: Interdigital Disease

A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.

Reference Drug

9.0
Participants

Test Drug

9.0
Participants

Control

1.0
Participants

Complete Cure Rate: Moccasin Disease

A negative KOH and negative culture and no evidence of clinical disease as indicated by scores of 0 for each sign and symptom at Day 43.

Reference Drug

2.0
Participants

Test Drug

Control

Effective Treatment: Interdigital Disease

Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).

Reference Drug

21.0
Participants

Test Drug

16.0
Participants

Control

1.0
Participants

Effective Treatment: Mocassin Disease

Negative KOH, negative fungal culture, no or mild (a score of 0 or 1) erythema and/or scaling with all other signs or symptoms being absent (score = 0) at Day 43 (Week6).

Reference Drug

3.0
Participants

Test Drug

4.0
Participants

Control

Mycological Cure: Interdigital Disease

Negative KOH and negative fungal culture at Day 43

Reference Drug

27.0
Participants

Test Drug

20.0
Participants

Control

4.0
Participants

Mycological Cure: Mocassin Disease

Negative KOH and negative fungal culture at Day 43

Reference Drug

5.0
Participants

Test Drug

5.0
Participants

Control

1.0
Participants

Total

135
Participants

Age Continuous

44.2
years (Mean)
Standard Deviation: 13.8

Weight

200.4
lbs (Mean)
Standard Deviation: 50.42

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Reference Drug

Test Drug

Control